Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 28;12:3295. doi: 10.1038/s41598-022-07305-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Generation of iPSDCs from patient-derived autologous iPSCs and their cell characterization in comparison to BMDCs. (a) List of colorectal cancer samples. The HLA-A allele was determined using an HLA-A High Resolution Typing System. Neoantigen analysis was performed in Case 3. Abbreviation Description S is sigmoid colon, T is transverse colon, Ra is upper rectum, tub1 is well-differentiated adenocarcinoma, and tub2 is moderately-differentiated adenocarcinoma. (b) Characterization of autologous iPSCs derived from a patient, Case 1. Alkaline phosphatase staining and fluorescent staining with undifferentiated markers showed pluripotency of iPSCs. Scale bars = 80 μm. (c) Karyotyping of iPSCs. No chromosomal abnormalities were found in these chromosomes in Case 1, 2, and 3. (d) The schematic diagram of differentiation protocol for iPSDCs. Scale bars = 80 μm (Before Day 16). Scale bars = 20 μm (After Day 21). (e) Morphology showing mature BMDCs (left) and mature iPSDCs (right) derived by Case 1. Scale bars = 20 μm. (f) Surface phenotypes of BMDCs (left) and iPSDCs (right) derived from the same cancer patient, Case 3. Black-filled histograms represent the staining results of specific antibodies. Gray lines highlight isotype-matched controls. (g) The expression of HLA-A on mature iPSDCs and BMDCs. Black-filled highlight the staining results of HLA-A. Gray lines histograms represent the isotype-matched controls. (h) The secretion of IFN-γ, IL-12(p70) and TNF-α from BMDCs and iPSDCs was examined by ELISA assay. Data represent the mean ± SD (three donors for each group).

Generation of iPSDCs from patient-derived autologous iPSCs and their cell characterization in comparison to BMDCs. (a) List of colorectal cancer samples. The HLA-A allele was determined using an HLA-A High Resolution Typing System. Neoantigen analysis was performed in Case 3. Abbreviation Description S is sigmoid colon, T is transverse colon, Ra is upper rectum, tub1 is well-differentiated adenocarcinoma, and tub2 is moderately-differentiated adenocarcinoma. (b) Characterization of autologous iPSCs derived from a patient, Case 1. Alkaline phosphatase staining and fluorescent staining with undifferentiated markers showed pluripotency of iPSCs. Scale bars = 80 μm. (c) Karyotyping of iPSCs. No chromosomal abnormalities were found in these chromosomes in Case 1, 2, and 3. (d) The schematic diagram of differentiation protocol for iPSDCs. Scale bars = 80 μm (Before Day 16). Scale bars = 20 μm (After Day 21). (e) Morphology showing mature BMDCs (left) and mature iPSDCs (right) derived by Case 1. Scale bars = 20 μm. (f) Surface phenotypes of BMDCs (left) and iPSDCs (right) derived from the same cancer patient, Case 3. Black-filled histograms represent the staining results of specific antibodies. Gray lines highlight isotype-matched controls. (g) The expression of HLA-A on mature iPSDCs and BMDCs. Black-filled highlight the staining results of HLA-A. Gray lines histograms represent the isotype-matched controls. (h) The secretion of IFN-γ, IL-12(p70) and TNF-α from BMDCs and iPSDCs was examined by ELISA assay. Data represent the mean ± SD (three donors for each group).